Press release
Parkinson's Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal
DelveInsight's "Parkinson's Disease Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Parkinson's Disease, historical and forecasted epidemiology as well as the Parkinson's Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Parkinson's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson's Disease Market Forecast [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Parkinson's Disease Market Report:
* The Parkinson's Disease market size was valued approximately USD 3,226 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
* In 2022, the United States recorded the highest number of diagnosed prevalent cases of Parkinson's disease, totaling approximately 1,152,195 cases, while Italy reported the lowest incidence, with nearly 152,237 cases.
* In 2022, Parkinson's disease affected approximately 660,458 males and 491,736 females in the United States. It is projected that the prevalence of the disease will continue to rise by 2032.
* In 2022, Germany recorded the highest number of diagnosed prevalent cases of Parkinson's disease among EU4 and the UK countries, totaling around 454,448 cases. France followed with approximately 264,695 cases in the same year.
* The analysis suggests that approximately 501,726 cases were diagnosed among individuals aged over 75 years. The majority of cases occur in the elderly population.
* In 2022, the highest prevalence was observed in the stage III group, comprising 587,965 cases, followed by stage IV with 269,729 cases. It is anticipated that the number of cases will rise in the forecast period.
* Key Parkinson's Disease Companies: AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial - Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
* Key Parkinson's Disease Therapies: ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
* The Parkinson's Disease epidemiology based on gender analyzed that there is male preponderance in the Parkinson's disease cases in the 7MM
* The Parkinson's Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson's Disease pipeline products will significantly revolutionize the Parkinson's Disease market dynamics.
Parkinson's Disease Overview
Parkinson's disease is a neurodegenerative disorder that primarily affects movement. It is characterized by a progressive loss of neurons in the brain, particularly in a region called the substantia nigra, which is responsible for producing dopamine, a neurotransmitter involved in movement control.
Get a Free sample for the Parkinson's Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment [https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Parkinson's Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Parkinson's Disease Epidemiology Segmentation:
The Parkinson's Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
* Total Prevalence of Parkinson's Disease
* Prevalent Cases of Parkinson's Disease by severity
* Gender-specific Prevalence of Parkinson's Disease
* Diagnosed Cases of Episodic and Chronic Parkinson's Disease
Download the report to understand which factors are driving Parkinson's Disease epidemiology trends @ Parkinson's Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Parkinson's Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson's Disease market or expected to get launched during the study period. The analysis covers Parkinson's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Parkinson's Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Parkinson's Disease Therapies and Key Companies
* ABBV-951: AbbVie
* ND0612: Mitsubishi Tanabe Pharma(NeuroDerm)
* CVN-424: Cerevance
* IPX203: Amneal Pharmaceutical
* P2B001: Pharma Two B
* Suvecaltamide (JZP385): Jazz Pharmaceuticals
* CTC-413: Chase Therapeutics Corporation
* MT101-5: Mthera Pharma Co., Ltd.
* BIA 28-6156: Bial R&D Investments, S.A.
* RO7046015: Hoffmann-La Roche
* ND0612: NeuroDerm Ltd.
* pimavanserin tartrate: Tasly Pharmaceutical
* Ceftriaxone: BrainX Corporation
* UCB0599: UCB Biopharma SRL
* Tocovid Suprabio (HOV-12020): National Neuroscience Institute
* Altropane (123I) Injection: GE Healthcare
* Tavapadon: Cerevel Therapeutics, LLC
* IkT-148009: Inhibikase Therapeutics, Inc.
* Opicapone: Bial - Portela C S.A.
* NLY01: Neuraly, Inc.
* Gemfibrozil: Forest Hills Lab
* Lenrispodun: Intra-Cellular Therapies, Inc.
* KM-819: FAScinate Therapeutics Inc.
* ACI-7104.056: AC Immune SA
Discover more about therapies set to grab major Parkinson's Disease market share @ Parkinson's Disease Treatment Landscape [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Parkinson's Disease Market Drivers
* Growing research and development are increasing the demand for better diagnosis and treatment options for Parkinson's Disease.
* In recent years, drugs with a novel mechanism of action and combinations are being investigated to overcome the challenges of this entity
Parkinson's Disease Market Barriers
* The development of a disease-modifying drug can potentially increase the Parkinson's Disease market share potential.
* In advanced countries, there is a huge annual psychological, social, and economic burden (QALY) due to Parkinson's Disease.
Scope of the Parkinson's Disease Market Report
* Study Period: 2019-2032
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Parkinson's Disease Companies: AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharmaceutical, Pharma Two B, Jazz Pharmaceuticals, Chase Therapeutics Corporation, Mthera Pharma Co., Ltd., Bial R&D Investments, S.A., Hoffmann-La Roche, NeuroDerm Ltd., Tasly Pharmaceutical, BrainX Corporation, UCB Biopharma SRL, National Neuroscience Institute, GE Healthcare, Cerevel Therapeutics, LLC, Inhibikase Therapeutics, Inc., Bial - Portela C S.A., Neuraly, Inc., Forest Hills Lab, Intra-Cellular Therapies, Inc., FAScinate Therapeutics Inc., AC Immune SA, and others
* Key Parkinson's Disease Therapies: ABBV-951, ND0612, CVN-424, IPX203, P2B001, Suvecaltamide (JZP385), CTC-413, MT101-5, BIA 28-6156, RO7046015, ND0612, pimavanserin tartrate, Ceftriaxone, UCB0599, Tocovid Suprabio (HOV-12020), Altropane (123I) Injection, Tavapadon, IkT-148009, Opicapone, NLY01, Gemfibrozil, Lenrispodun, KM-819, ACI-7104.056, and others
* Parkinson's Disease Therapeutic Assessment: Parkinson's Disease current marketed and Parkinson's Disease emerging therapies
* Parkinson's Disease Market Dynamics: Parkinson's Disease market drivers and Parkinson's Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Parkinson's Disease Unmet Needs, KOL's views, Analyst's views, Parkinson's Disease Market Access and Reimbursement
To know more about Parkinson's Disease companies working in the treatment market, visit @ Parkinson's Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-market-size-analysis-treatment?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Parkinson's Disease Market Report Introduction
2. Executive Summary for Parkinson's Disease
3. SWOT analysis of Parkinson's Disease
4. Parkinson's Disease Patient Share (%) Overview at a Glance
5. Parkinson's Disease Market Overview at a Glance
6. Parkinson's Disease Disease Background and Overview
7. Parkinson's Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Parkinson's Disease
9. Parkinson's Disease Current Treatment and Medical Practices
10. Parkinson's Disease Unmet Needs
11. Parkinson's Disease Emerging Therapies
12. Parkinson's Disease Market Outlook
13. Country-Wise Parkinson's Disease Market Analysis (2019-2032)
14. Parkinson's Disease Market Access and Reimbursement of Therapies
15. Parkinson's Disease Market Drivers
16. Parkinson's Disease Market Barriers
17. Parkinson's Disease Appendix
18. Parkinson's Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-market-is-expected-to-expand-at-a-healthy-growth-rate-during-the-forecast-period-20232032-states-delveinsight-abbvie-mitsubishi-tanabe-pharma-neuroderm-cerevance-amneal]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal here
News-ID: 3472140 • Views: …
More Releases from ABNewswire
What are the most effective medical therapies for managing excess body mass? Reg …
Cape Coral healthcare providers report breakthrough success using FDA-approved GLP-1 medications for weight management, with Premier Wellness Florida leading comprehensive treatment programs combining pharmaceuticals with holistic wellness support.
Cape Coral, FL - Recent clinical developments in medical weight management have prompted Southwest Florida healthcare providers to report significant patient success rates with FDA-approved medications and comprehensive treatment protocols. Premier Wellness Florida, operating from its Del Prado Boulevard facility, has documented patient…
Winkler Kurtz LLP - Long Island Lawyers Port Jefferson Station Injury Attorney O …
Winkler Kurtz LLP is a leading Long Island law firm specializing in personal injury cases such as car accidents, slip and falls, and medical malpractice. Offering decades of local experience, the firm provides compassionate support and skilled legal advocacy to help injury victims secure justice and compensation. With free consultations and a contingency fee policy, Winkler Kurtz LLP ensures quality legal help is available to all Long Islanders in need.
When…
How to Pick the Best Online Chemistry Tutoring Platform
Image: https://www.abnewswire.com/upload/2025/10/814f4b38d9855ce5fcc0509bfebaa240.jpg
Choosing the right chemistry tutoring platform can make the difference between academic success and continued struggles with complex reactions and molecular structures. With students increasingly turning to digital solutions for personalized learning support, the online chemistry tutoring market has exploded with options promising everything from AI-powered progress tracking to virtual lab experiences that transform how learners approach this challenging subject.
Essential Platform Features for Effective Online Chemistry Tutoring
Modern chemistry tutoring…
Chronic Myeloid Leukemia Pipeline Drugs Report 2025: Emerging Therapies, Clinica …
DelveInsight's "Chronic Myeloid Leukemia Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Chronic Myeloid Leukemia pipeline landscape. It covers the Chronic Myeloid Leukemia Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Myeloid Leukemia Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious…
More Releases for Parkinson
Key Trends Reshaping the Wolff Parkinson White Syndrome Market: Technological Ad …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
Wolff Parkinson White Syndrome Market Size Growth Forecast: What to Expect by 2025?
The market for Wolff Parkinson White syndrome has registered consistent growth over the recent past. The expectation is that it will expand from $1.17 billion in 2024 to $1.22 billion in 2025, reflecting a compound annual growth rate (CAGR) of 4.5%.…
Evolving Market Trends In The Anti-Parkinson Drugs Industry: Innovative Advancem …
The Anti-Parkinson Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Anti-Parkinson Drugs Market Size During the Forecast Period?
The anti-parkinson drugs market has seen significant growth in recent years, projected to increase from $10.37 billion in 2024 to $11.08 billion in…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
What's Driving the Anti-Parkinson Drugs Market 2025-2034: Increasing Geriatric P …
What Are the Projections for the Size and Growth Rate of the Anti-Parkinson Drugs Market?
In recent times, the market size for anti-Parkinson drugs has experienced robust growth. The market, which is projected to rise from $10.37 billion in 2024 to $11.08 billion in 2025, boasts a compound annual growth rate (CAGR) of 6.9%. The past growth trend can be credited to an aging demographic, a surge in disease incidence, enhanced…
Wolff Parkinson White Syndrome Treatment Market Overview 2024-2033
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Wolff Parkinson White Syndrome Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $1.43 billion…
Anti-Parkinson Drugs Market Overview
Exhibiting robust growth, the anti-parkinson drugs market is set to escalate from $9.73 billion in 2023 to $10.43 billion in 2024, with a notable Compound Annual Growth Rate (CAGR) of 7.2%. The trajectory continues on an upward trend, with an anticipated market size of $13.36 billion by 2028, sustaining a robust CAGR of 6.4%.
Increasing Geriatric Population Driving Demand:
The burgeoning geriatric population, coupled with a surge in Parkinson's disease cases,…
